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Background
Previously we identified patient H19659 who early in his
progressive course of infection had HIV-1 variants that
were relatively sensitive to neutralization by b12, but who
later in infection developed viruses that were highly resist-
ant to b12 neutralization. This increased b12 resistance
coincided with an increase in viral replicative capacity.
Here we investigated which changes in Env accounted for
the differences in replication rate and sensitivity to b12
neutralization between HIV-1 variants that were isolated
early and late in the course of infection from this patient
and whether immune pressure in vivo was involved in
selection of viruses.
Methods
Gp120 sequences were generated from clonal HIV-1 vari-
ants and amino acid changes that segregated with differ-
ences in b12 neutralization sensitivity and replication rate
were created in the background of molecular clone LAI.
LAI mutants were tested for replication rate and b12 neu-
tralization sensitivity. CTL pressure on amino acids
involved in the b12 epitope sequence was tested by ELIS-
POT with patient PBMC.
Results
Sequence analysis of Env mutations in clonal HIV-1 vari-
ants suggested involvement of substitutions I154M (in
V1) K178T (in V2) and Q389K (in V4) in the b12 resist-
ance of viruses from patient H19659. Indeed, any combi-
nation of these mutations in the background of LAI
increased the resistance to b12 neutralization. However,
in the LAI background, these mutations reduced the repli-
cative capacity, suggesting the presence of compensatory
mutations in the rapidly replicating b12 resistant primary
virus variants. Interestingly, this individual had only weak
autologous and heterologous neutralizing activity in
serum, and no detectable CTL response against HLA-
restricted epitopes that contained b12 resistance muta-
tions.
Conclusion
In patient H19659, rapidly replicating b12 resistant HIV-
1 variants emerged during the course of infection in the
absence of immune pressure. In light of vaccine design, it
may be important to understand how these neutralization
resistant viruses were selected.
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